Clinical Studies of Safety and Effectiveness of Orphan Products

The summary for the Clinical Studies of Safety and Effectiveness of Orphan Products grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.
Clinical Studies of Safety and Effectiveness of Orphan Products: Please note that there is only one receipt date for FY 2009 and one receipt date for FY 2010.1. BackgroundOPD was created to identify andpromote the development of orphanproducts. Orphan products are drugs,biologics, medical devices, and foods formedical purposes that are indicated fora rare disease or condition (that is, onewith a prevalence, not incidence, offewer than 200,000 people in the UnitedStates). Diagnostic tests and vaccines will qualify only if the U.S. populationof intended use is fewer than 200,000people a year. Additional informationabout OPD is available on FDAs Website at www.fda.gov/orphan.2. Program Research GoalsThe goal of FDAs OPD grant programis to support the clinical development ofproducts for use in rare diseases orconditions where no current therapyexists or where the product willimprove the existing therapy. FDAprovides grants for clinical studies onsafety and/or effectiveness that willeither result in, or substantiallycontribute to, market approval of theseproducts. Applicants must include inthe applications Background andSignificance section documentation tosupport the estimated prevalence of theorphan disease or condition and anexplanation of how the proposed studywill either help gain product approvalor provide essential data needed forproduct development. All fundedstudies are subject to the requirementsof the Federal Food, Drug, and CosmeticAct (the act) (21 U.S.C. 331 et seq.),regulations issued under it, andapplicable Department of Health andHuman Services (HHS) statutes andregulations.Inclusion of Women And Minorities inClinical ResearchApplicants for PHS clinical researchgrants are encouraged to includeminorities and women in studypopulations so research findings can beof benefit to all people at risk of thedisease or condition under study. It isrecommended that applicants placespecial emphasis on includingminorities and women in studies ofdiseases, disorders, and conditions thatdisproportionately affect them. Thispolicy applies to research subjects of allages. If women or minorities areexcluded or poorly represented inclinical research, the applicant shouldprovide a clear and compelling rationalethat shows inclusion is inappropriate.Inclusion of Children as Participants inClinical Research.FDA regulations at 21 CFR part 50,subpart D contain additionalrequirements that must be met by IRBsreviewing clinical investigationsregulated by FDA and involvingchildren as subjects. FDA is part ofHHS; accordingly, the research projectgrants under this program are supportedby HHS, and HHS regulations at 45 CFRpart 46, subpart D also apply to researchinvolving children as subjects.Standards for Privacy of IndividuallyIdentifiable Health InformationHHS issued final modification to theStandards for Privacy of IndividuallyIdentifiable Health Information, thePrivacy Rule, on August 14, 2002.The Privacy Rule is a federal regulationunder the Health Insurance Portabilityand Accountability Act (HIPAA) of 1996that governs the protection ofindividually identifiable healthinformation, and is administered andenforced by the HHS Office for CivilRights (OCR).PHS is committed to achieving thehealth promotion and diseaseprevention objectives of HealthyPeople 2010, a PHS-led nationalactivity for setting priority areas. ThisFunding Opportunity Announcement isrelated to one or more of the priorityareas. Potential applicants may obtain a copy of Healthy People 2010 at http://www.health.gov/healthypeople.Smoke-Free WorkplaceThe PHS strongly encourages all grantrecipients to provide a smoke-freeworkplace and discourage the use of alltobacco products. In addition, PublicLaw 103-227, the Pro-Children Act of1994, prohibits smoking in certainfacilities (or in some cases, any portionof a facility) in which regular or routineeducation, library, day care, health care,or early childhood developmentservices are provided to children. Thisis consistent with the PHS mission toprotect and advance the physical andmental health of the American people.
Federal Grant Title: Clinical Studies of Safety and Effectiveness of Orphan Products
Federal Agency Name: Food and Drug Administration
Grant Categories: Science and Technology Health
Type of Opportunity: Discretionary
Funding Opportunity Number: FD08-001
Type of Funding: Grant
CFDA Numbers: 93.103
CFDA Descriptions: Food and Drug Administration_Research
Current Application Deadline: No deadline provided
Original Application Deadline: Sep 26, 2007 This FOA FD08-001 has been temporari
Posted Date: Jul 06, 2007
Creation Date: Dec 05, 2008
Archive Date: Feb 15, 2008
Total Program Funding: $4,200,000
Maximum Federal Grant Award: $400,000
Minimum Federal Grant Award: $200,000
Expected Number of Awards: 12
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply. For profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities, as described in section 501(c)(4) of the Internal Revenue Code of 1968, are not eligible to receive grant awards. An application that has received two prior disapprovals is not eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
Marc Pitts
Senior Grants Management Specialist
Phone 301-827-7162 [email protected] [email protected]
Similar Government Grants
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical T...
Single Source Cooperative Agreement to Support HPAI H5N1 Research at Cornell University (U...
Animal and Veterinary Innovation Centers (U18)
Cooperative Agreement to Support the Illinois Institute of Technology's Institute for Food...
Minor Use Minor Species Development of Drugs (R01)
Support for Small Scientific Conference Grant Program
Cooperative Agreement to Support the World Health Organization (WHO) International Program...
FDA State Food Safety Task Force Conference
More Grants from the Food and Drug Administration
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical T...
Single Source Cooperative Agreement to Support HPAI H5N1 Research at Cornell University (U...
Animal and Veterinary Innovation Centers (U18)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com